CytoMed Therapeutics

CytoMed Therapeutics

Biotechnology
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

$10.6M

Market Cap • 10/9/2026

2018

(8 years)

Founded

2023

(3 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Singapore

Singapore

Country

Valuation

P/B

2,8

P/S

42,1

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,3

EPS

—

Market Cap

Market Cap

10,6M

EV

10,1M

EV/Revenue

40,3

EV/EBITDA

-3,8

EV/EBIT

-3,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-2,1%

Total Yield

-2,1%

Payout

0%

Retained Earnings

-15,9M

Profitability

Gross Margin

75,9%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

659,5%

Capex/Revenue

145,9%

Capex/D&A

103,5%

Capex/OCF

-12,7%

SBC/OCF

—

% PPE

52%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

21,6%

CAGR Net Income 5Y

8,1%

CAGR EPS 5Y

-6,4%

CAGR OCF 5Y

30,3%

Leverage

N.D./EBITDA

0,3

Debt/Equity

0%

Current Ratio

2,6

Quick Ratio

2,6

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium